CNXC Stock Forecast & Price Target

Concentrix is attractive because the stock trades at under 4x EV/EBITDA on CY27E with a free cash flow yield in the mid-40s to north of 50%, while management’s roughly $2B of projected free cash flow over the next three years exceeds today’s equity value. The company is also strengthening its quality of growth, as FY27 revenue is expected to exceed $6B, iX retention is roughly four times that of the traditional business, and fiscal Q2/26 showed an 80% increase in high-end technology deals plus record iX Suite signings up 400% year-over-year. Balance-sheet improvement adds further support, with net debt at about $4.12B after $211M of reduction, year-end net debt expected near $3.8B, and another $550M+ of gross debt reduction targeted in FY27 as buybacks pause in favor of deleveraging.

Concentrix is facing a negative fundamental reset because revenue guidance was cut for the second straight quarter, with Q3 constant-currency revenue down 0.5% and Q4 now guided to a 3% to 5% decline, implying full-year FY26 revenue of $9.827 billion to $9.877 billion and a 0.3% to 0.8% constant-currency decline. The deterioration reflects secular and client-specific headwinds, including accelerated offshoring, reduced support for certain client segments, and a hyperscaler exit that compressed faster than expected, while healthcare, technology, and other verticals remain soft. Although Q4 non-GAAP operating margin is expected to improve to about 12.9%, the combination of lower growth, recurring guidance cuts, $175 million of restructuring charges, and 3.0x net debt to TTM adjusted EBITDA leaves the risk/reward unattractive.